Oxaliplatin Combined with 5-Fluorouracil and Methotrexate in Advanced Colorectal Cancer

• Published in: Anticancer research Vol. 26; no. 3B; pp. 2425 - 2428
• Main Authors: ZAMPINO, M. G, LORIZZO, K, ROCCA, A, LOCATELLI, M, ZORZINO, L, MANZONI, S, MAZZETTA, C, FAZIO, N, BIFFI, R, DE BRAUD, F
• Format: Journal Article
• Language: English
• Published: Attiki International Institute of Anticancer Research 01.05.2006
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Colorectal Neoplasms - blood; Colorectal Neoplasms - drug therapy; Drug Administration Schedule; Female; Fluorouracil - administration & dosage; Fluorouracil - adverse effects; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Infusions, Intravenous; Male; Medical sciences; Methotrexate - administration & dosage; Methotrexate - adverse effects; Middle Aged; Organoplatinum Compounds - administration & dosage; Organoplatinum Compounds - adverse effects; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Tumors; Vascular Endothelial Growth Factor A - blood; Antineoplastic agent; Rectal disease; Colorectal cancer; Antifolate; Cancerology; Oxaliplatin; Advanced colorectal cancer; Intestinal disease; Advanced stage; Methotrexate; Platinum II Complexes; Fluorouracil; Enzyme; Fluoropyrimidine derivatives; Transferases; VEGF; Enzyme inhibitor; Malignant tumor; Thymidylate synthase; Colonic disease; Alkylating agent; Vascular endothelium growth factor; Antimetabolic; Methyltransferases; Digestive diseases; Pyrimidine derivatives
• ISSN: 0250-7005; 1791-7530

Background: A promising regimen including 5-Fluorouracil, methotrexate and oxaliplatin is reported. Patients and Methods: Patients with untreated measurable metastatic disease received bolus 5-Fluorouracil (600 mg/m 2 ) on days 2 and 16, modulated by methotrexate (200 mg/m 2 ) 24 h earlier, alternated with 4 weeks of continuous infusion of 5-Fluorouracil (200 mg/m 2 /daily) plus oxaliplatin (130 mg/m 2 ) on days 29 and 56, followed by 2 weeks of rest. Serum vascular endothelial growth factor (VEGF) was analyzed at baseline and before every cycle. Results: Fifty-eight patients were enrolled. Objective remissions were reported in 45.6% (95% CI=34.3%, 57.3%). The median progression-free survival was 7.8 months and the median overall survival was 19.4 months. No grade 4 toxicity was reported, except for one case of diarrhea. The serum VEGF evaluated in 23 patients showed a decreasing trend during therapy. Conclusion: The regimen was active, well tolerated and may be a possible option in patients not suitable for radical surgery.